INNOVIVA, INC. (INVA) Debt / Equity
- 2017-06-30: Debt/Equity Ratio -2.2.
- 2016-12-31: Debt/Equity Ratio -2.03.
- 2016-06-30: Debt/Equity Ratio -2.
- 2015-12-31: Debt/Equity Ratio -2.14.
Complete source-backed debt/equity ratio history.
- Available history
- 2015-12-31 to 2017-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2017-06-30 | -2.2 |
| 2016-12-31 | -2.03 |
| 2016-06-30 | -2 |
| 2015-12-31 | -2.14 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2016-12-31 | -2.03 |
| 2015-12-31 | -2.14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |